Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)

In brief

Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT) on ALP and bilirubin compared to sham transplantation in addition to ursodeoxycholic acid (UDCA) treatment in PSC patients.

Key facts

Study ID

NCT07477782

Run by

Assistance Publique - Hôpitaux de Paris

People needed

72

Starts

2026-05-01

Expected to finish

2030-05-01

Last updated by the study team

2026-03-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females
• Age ≥18 and ≤75 years
• Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
• IBD diagnosed according to international guidelines (presence of endoscopic and histologic signs)
• IBD inactive for at least 6 months (defined by no evidence of flare and no change in treatment)
• ALP ≥ 1.3 ULN (at least 2 times within a 3 months pre-inclusion period) or elevated total bilirubin ≤50 umol/l (with concomitant elevated direct bilirubin).
• Treatment with UDCA (13-23 mg/kg/d) for at least 6 months and at the same dosage for at least 3 months
• Using contraceptive in women of childbearing potential and agrees to pursue it from inclusion until week 48. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly.
• Written informed consent signed
• Subject affiliated to the French
• Social Security System

You may not qualify if…

• Small duct PSC
• Autoimmune hepatitis defined by the presence of moderate to severe interface hepatitis documented on liver biopsy and at least 1 of the 2 following criteria: AST or ALT > 5 ULN, Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
• Secondary sclerosing cholangitis (notably IgG4-associated cholangitis)
• Cirrhosis defined by Liver elastometry >14.4 kPa or by current or past decompensation of cirrhosis
• AST or ALT > 7 ULN in the last 3 months
• Platelets count in the last 3 months < 100 000/mm3
• Albumin in the last 3 months <35g/L
• Prothrombin index in the last 3 months < 70%
• Hepatic comorbidity: HBV infection (defined by positive Ag HBS), HCV infection (defined by positive HCV RNA), alcohol abuse (defined by alcohol intake > 30g/day), metabolic dysfunction associated steatohepatitis, primary biliary cholangitis, Hemochromatosis, Wilson disease, α1-antitrypsin deficiency, celiac disease
• History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis
• HIV infection
• Prior liver transplantation
• Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
• History of or established or suspected hepatobiliary carcinoma.
• Any severe comorbidity that may reduce life expectancy
• History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to inclusion)
• Dosage changes of treatment for liver disease in the last 3 months or new treatment for liver disease started in the last 3 months
• History of colorectal carcinoma or high-grade dypsplasia in previous screening colonoscopy
• History of total colectomy
• Current active IBD defined by a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn's Disease Activity Index (CDAI) > 150 in patients with Crohn's disease
• Changes in IBD treatment or initiation of a new treatment for IBD in the last 3 months
• Current treatment with biologics (anti-TNF agent, vedolizumab, ustekinumab) or JAK inhibitors (tofacitinnib) or prednisone > 10 mg/day or budesonide > 3 mg /day) (or treatment initiated less than one month)
• Any contra-indication to swallow capsules
• Renal insufficiency (clearance<60 ml/min)
• Unable to consent, subject to legal or administrative decision (protection measure or deprivation of liberty) or involuntary psychiatric care.

Where it is running

• Hepatology Department, Saint Antoine Hospital — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.